Compass Therapeutics (NASDAQ:CMPX) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Compass Therapeutics (NASDAQ:CMPX - Free Report) had its target price hoisted by Jefferies Financial Group from $7.00 to $8.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

CMPX has been the topic of a number of other research reports. Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 15th. HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partners cut Compass Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, D. Boral Capital reissued a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.17.

Compass Therapeutics Stock Down 8.0 %

Shares of NASDAQ:CMPX traded down $0.30 on Monday, reaching $3.45. 1,260,215 shares of the company's stock were exchanged, compared to its average volume of 2,317,134. The business's 50-day moving average is $2.24 and its two-hundred day moving average is $1.78. The firm has a market capitalization of $474.68 million, a price-to-earnings ratio of -9.32 and a beta of 1.17. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its holdings in shares of Compass Therapeutics by 160.9% in the 4th quarter. XTX Topco Ltd now owns 52,754 shares of the company's stock worth $76,000 after purchasing an additional 32,533 shares during the period. Mariner LLC purchased a new stake in shares of Compass Therapeutics in the 4th quarter worth $30,000. Barclays PLC raised its position in shares of Compass Therapeutics by 13.2% in the 4th quarter. Barclays PLC now owns 192,766 shares of the company's stock worth $279,000 after acquiring an additional 22,521 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Compass Therapeutics by 25.2% in the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after acquiring an additional 56,000 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company's stock worth $57,000 after acquiring an additional 4,018 shares in the last quarter. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.